CYTORA at BioMed Israel 2025: Harnessing the unique potential of human oral mucosa stem cell (hOMSC) for treating complex multifactorial diseases.

Dr. Yona Geffen, CEO of Cytora presented how the unique potential of human oral mucosa stem cells (hOMSC) to treating multifactorial diseases as part of the Genetic and Cellular Advances for Rare and Complex Diseases session. hOMSC are a unique population of stem cells originating from the neural crest. In the oral cavity, they mediate rapid wound healing compared to other tissues, promote full tissue regeneration, without scarring, and their activity is not affected by age. hOMSC are easily propagated without losing their unique stem-cell properties – a tiny biopsy of 4x3x2 mm from a healthy donor generates doses for thousands of doses. thus, enabling the production of an “off the shelf” stem cell treatment platform for human use. Results of Cytora’s two clinical programs phase 1/2a for DFU and phase 1 ongoing study for MSA were presented.